Board of Directors of Artgen Biotech decided the issue of additional share issue itself

Board of Directors of Artgen Biotech canceled the shareholders' meeting, which was supposed to resolve the issue of increasing the authorized capital by 7.5% by placing additional shares. At the same time, the Board of Directors itself decided to place 17,354,549 additional shares of the company by public subscription in 2024. Raised funds as a result of the additional share issue are planned to be used for development and expansion of the development portfolio and production base in 2024-2026.